Woolfson A, Huebner R, Wasas A, Chola S, Godfrey-Faussett P, Klugman K
Department of Medicine, John Radcliffe Hospital, University of Oxford, England.
Bull World Health Organ. 1997;75(5):453-62.
The emergence of antibiotic-resistant Streptococcus pneumoniae is an international health problem. Apart from South Africa few data on pneumococcal resistance are available for sub-Saharan Africa. This study examines the nasopharyngeal carriage and prevalence of antibiotic resistance in pneumococci isolated from 260 Zambian children aged < 6 years. Pneumococci were isolated from 71.9% of the children; the odds of carrying organisms were twice as high among children < 2 years of age compared with older children. Antibacterial resistance was found in 34.1% of the isolates; resistance to tetracycline, penicillin, sulfamethoxazole + trimethoprim, and chloramphenicol occurred in 23.0%, 14.3%, 12.7%, and 3.9% of the isolates, respectively. Only 4% of the isolates were resistant to three drugs. High-level resistance was found in all isolates resistant to tetracycline; but only intermediate level penicillin resistance was found. A total of 11.1% of the isolates demonstrated intermediate resistance to sulfamethoxazole + trimethoprim. Children aged < 6 months were less likely to carry antibiotic-resistant organisms. Antibiotic resistance in S. pneumoniae appears to be an emerging public health problem in Zambia, and the national policy for the empirical treatment of pneumococcal meningitis and acute respiratory tract infections may need to be re-evaluated. The establishment of ongoing surveillance to monitor trends in pneumococcal resistance should be considered.
肺炎链球菌耐药性的出现是一个国际卫生问题。除南非外,撒哈拉以南非洲地区关于肺炎球菌耐药性的数据很少。本研究调查了从260名6岁以下赞比亚儿童分离出的肺炎球菌的鼻咽部携带情况及抗生素耐药性流行情况。71.9%的儿童分离出了肺炎球菌;2岁以下儿童携带肺炎球菌的几率是大龄儿童的两倍。34.1%的分离株发现有抗菌药物耐药性;对四环素、青霉素、磺胺甲恶唑+甲氧苄啶和氯霉素的耐药率分别为23.0%、14.3%、12.7%和3.9%。仅4%的分离株对三种药物耐药。所有对四环素耐药的分离株均发现有高水平耐药;但仅发现有中度青霉素耐药。共有11.1%的分离株对磺胺甲恶唑+甲氧苄啶表现出中度耐药。6个月以下儿童携带耐药菌的可能性较小。肺炎链球菌的抗生素耐药性在赞比亚似乎是一个新出现的公共卫生问题,可能需要重新评估该国针对肺炎球菌性脑膜炎和急性呼吸道感染的经验性治疗政策。应考虑建立持续监测以监测肺炎球菌耐药性趋势。